At first glance Veru, Inc.’s (NASDAQ: VERU) COVID-19 therapy phase 3 top line results were notable but their battle for an emergency...
Pfizer’s (NYSE: PFE) PAXLOVID has risen to prominence as the top COVID-19 antiviral in the world. The speed at which they rose...
Vaccines have less efficacy with COVID-19 variants Key 3CL protease inhibitors shows promise for any COVID-19 variants, and potentially all coronav...
6 endpoints met after full data release so shorts double down on trial failure narrative Investors in CytoDyn Inc. (OTCMKTS: CYDY) are...
Powerful recommendation from DSMB Imminent on Leronlimab Numbers are not part of any Interim report unless a statistical penalty is taken A...
CytoDyn Inc. (OTCMKTS: CYDY) announced groundbreaking safety results from its phase 2 Mild to Moderate COVID-19 trial today. The company reported ...
Today Gilead Sciences (NASDAQ: GILD) was making a splash about their phase 3 trial results but all this trial essentially did was...
CytoDyn Inc. (OTCMKTS: CYDY) announced today it was collaborating with the United Kingdom’s Department of Health to provide emergency access to ler...
Developing a vaccine to treat COVID-19 is hands down the best way to play the long term coronavirus stocks. Ultimately a vaccine...